EyePoint Inc. has completed enrollment for its pivotal DURAVYU trials for diabetic macular edema, achieved in just five months with 480 patients. Topline data is anticipated in 4Q 2027, followed by FDA and EMA review.
EyePoint Inc. has completed enrollment for its pivotal DURAVYU trials for diabetic macular edema, achieved in just five months with 480 patients. Topline data is anticipated in 4Q 2027, followed by FDA and EMA review.